We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 11, 2021

Glofitamab Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
J. Clin. Oncol 2021 Mar 19;[EPub Ahead of Print], M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, A Sureda, G Salles, J Martínez-Lopez, M Crump, DN Thomas, PN Morcos, C Ferlini, AE Bröske, A Belousov, M Bacac, N Dimier, DJ Carlile, L Lundberg, D Perez-Callejo, P Umaña, T Moore, M Weisser, MJ Dickinson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading